Home › Funds › Latash Investments, LLC › AQST
Latash Investments, LLC position in AQST
AQUESTIVE THERAPEUTICS INC · Health Care
Latash Investments, LLC reported holding 243,134 shares of AQST (AQUESTIVE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.1M, representing 0.83% of its reported portfolio and ranking #7 among its reported holdings. Latash Investments, LLC has disclosed AQST holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Latash Investments, LLC's AQST position evolved
Latash Investments, LLC first disclosed a stake in AQST in Q3 2023 at 243,134 shares (US$372K). The position peaked in Q4 2025 at 243,134 shares, worth US$1.6M. Across 13 filings, Latash Investments, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 243,134 shares valued at US$1.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 243.13K | $372.00K | New |
| Q4 2023 | 243.13K | $491.13K | Hold |
| Q1 2024 | 243.13K | $1.04M | Hold |
| Q2 2024 | 243.13K | $632.15K | Hold |
| Q3 2024 | 243.13K | $1.21M | Hold |
| Q4 2024 | 243.13K | $865.56K | Hold |
| Q1 2025 | 243.13K | $705.09K | Hold |
| Q2 2025 | 243.13K | $804.77K | Hold |
| Q3 2025 | 243.13K | $1.36M | Hold |
| Q4 2025 | 243.13K | $1.57M | Hold |
| Q1 2026 | 243.13K | $1.01M | Hold |
| Q2 2026 | 243.13K | $1.01M | Hold |
| Q3 2026 | 243.13K | $1.13M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AQST and 13F data
AQST (AQUESTIVE THERAPEUTICS INC) is a Health Care company. 36 other funds we track also report a position in AQST — the largest reported positions include Bratton Capital Management, L.P. (US$45.4M), Samsara BioCapital, LLC (US$10.4M), Propel Bio Management, LLC (US$8.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AQST
- Bratton Capital Management, L.P. 9.81M sh · $45.42M · Q3 2026
- Samsara BioCapital, LLC 2.50M sh · $10.40M · Q2 2026
- Propel Bio Management, LLC 278.72K sh · $8.61M · Q3 2026
- Blue Owl Capital Holdings LP 1.39M sh · $6.44M · Q3 2026
- Sio Capital Management, LLC 1.49M sh · $6.18M · Q2 2026
- DAFNA Capital Management LLC 645.91K sh · $2.69M · Q2 2026
- Everstar Asset Management, LLC 611.94K sh · $2.55M · Q2 2026
- Bracebridge Capital, LLC 459.22K sh · $1.91M · Q2 2026
More on Latash Investments, LLC
FAQ
How long has Latash Investments, LLC held AQST?
Latash Investments, LLC has disclosed AQST holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Latash Investments, LLC's current position in AQST?
As of Q3 2026, Latash Investments, LLC holds 243.13K shares of AQST (AQUESTIVE THERAPEUTICS INC), valued at $1.13M, representing 0.83% of its reported portfolio and ranking #7.
Has Latash Investments, LLC been buying or selling AQST?
In the latest 13F filing (Q3 2026), Latash Investments, LLC held unchanged its position in AQST. The position peaked in Q4 2025 at 243.13K shares.
Which other funds hold AQST?
Other major institutional holders of AQST include Bratton Capital Management, L.P., Samsara BioCapital, LLC, Propel Bio Management, LLC, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.